Top Health care Stocks
Health care stocks were lower Thursday afternoon, with the NYSE
Health Care Sector Index falling 1.4% and shares of health care
companies in the S&P 500 down 1.5% as a group.
In company news, Pacira Pharmaceuticals Inc. (
) was higher this afternoon after the drug-maker reported a nearly
three-fold jump in revenue during the three months ended June 30
compared to the same quarter last year and narrowed its quarterly
net loss by two-thirds.
Its Q2 net loss was $5.0 million, or $0.14 per share, improving
on a $14.0 million net loss last year. Excluding non-recurring
items, the company earned $1.5 million, or $0.04 per share,
reversing a non-GAAP net loss of $10.8 million in the year-ago
period and crushing analyst expectations looking for a $0.21 per
share net loss.
Total revenues rose 276% year over year to $47.2 million, also
topping the Capital IQ consensus by $5.03 million. The quarter
included around $44.9 million in sales of the company's Exparel
nerve-block injection for post-surgical pain.
PCRX shares were ahead about 6.8% at $93.84 apiece in mid-day
trade, just under its session high of $93.94 a share. The stock has
traded within a 52-week range of $30.75 to $94.30 a share, rising
over 167% in value over the past 12 months.
In other sector news,
(+) HOLX, (+0.1%) Q3 EPS of $0.37 tops estimates by $0.03 per
share. Revenue advances 1% to $632.6 mln, beating consensus by
$10.78 mln. FY14 earnings forecasts is at least $0.04 better than
expectations; revenue outlook exceeds Street by at least $20
(-) EDAP, (-43.7%) FDA advisory panel votes 3-to-5 with one
abstention against the safety and 0-to-9 for the efficacy of its
Ablatherm-HIFU prostate cancer drug candidate. Vote on the
risk-benefit ratio was 0-to-8 against with one abstention.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.